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Background/aim: Phototherapy is a safe and effective treatment modality for numerous dermatological conditions. Recently, targeted
phototherapy modalities have gained importance due to their advantages over conventional phototherapy. This retrospective study
aimed to evaluate the safety and efficacy of targeted narrowband UVB phototherapy in patients with dermatological disorders.
Materials and methods: This single-center study included 173 patients who were treated with targeted narrowband UVB phototherapy.
Demographic features, phototherapy parameters, and adverse effects were evaluated in all patients, and the treatment response was
assessed in patients who attended at least one follow-up visit.
Results: A total of 173 patients (102 females; 71 males) with vitiligo, alopecia areata, lichen simplex chronicus, palmoplantar psoriasis,
and psoriasis vulgaris were included in the study. Among 73 patients, with whom the treatment was finalized by physician, an excellent
response was obtained in 10%, 52.9%, 53.8%, 28.6%, and 40% of patients with vitiligo, alopecia areata, lichen simplex chronicus,
palmoplantar psoriasis, and psoriasis, respectively. The treatment was generally well tolerated and was discontinued in only two patients
due to adverse effects.
Conclusion: This study demonstrates that targeted narrowband UVB therapy is a safe and effective treatment alternative, particularly
for alopecia areata, lichen simplex chronicus, and palmoplantar and plaque-type psoriasis.
Key words: Alopecia areata, lichen simplex chronicus, psoriasis, targeted phototherapy, ultraviolet B, vitiligo

1. Introduction
Phototherapy is a safe and effective treatment method
that utilizes ultraviolet radiation (UVR). Phototherapy
has an immunosuppressive effect on cutaneous T cells
and cytokines, and it is used in the treatment of various
dermatological conditions, including psoriasis, cutaneous
T cell lymphoma, and vitiligo (1). However, conventional
phototherapy methods have certain limitations in
localized diseases due to their acute and chronic adverse
effects. To that end, microphototherapy or targeted
phototherapy technologies have been developed. Targeted
phototherapy has several advantages over conventional
methods, such as not exposing healthy skin areas to
UVR and shorter treatment durations; as a result, the
inconvenience experienced by the patient lessens, and the
patient satisfaction and adherence to treatment increases
(2–6).
Several studies have investigated the efficacy of
microphototherapy, particularly for vitiligo and psoriasis
(3–5). However, the safety and efficacy of targeted

phototherapy in other dermatological diseases have not
been studied in detail.
The present study aimed to retrospectively evaluate
the safety and efficacy of NB-UVB microphototherapy in
various dermatological disorders.
2. Materials and methods
A retrospective chart review study was planned in order
to evaluate the safety and efficacy of targeted UVB therapy
in various cutaneous diseases. Our institutional ethics
committee reviewed and approved the study (approval
date/number: 09.12.2014/803).
2.1. Patient selection
All patients referred to our phototherapy unit for targeted
UVB therapy between 2014 and 2016 were included in the
study. All patients were unresponsive to previous topical
and/or systemic treatment attempts except for 18 patients
(10.5%) who did not receive any treatment before. The
medical charts and clinical photographs of all patients
were reviewed in order to analyze patient demographics,
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disease and treatment characteristics, phototherapy
parameters, treatment outcomes, and adverse effects.
2.2. Treatment protocol and its implementation
In our phototherapy unit, targeted UVB therapy was
performed with a Daavlin-Levia device (Bryan, Ohio,
USA) emitting NB-UVB radiation with a wavelength of
311–315 nm; the device is capable of treating an area of 3
cm2 with an output of 90 mW/cm2.
The minimal erythema dose (MED) was calculated for
the back skin in all patients prior to treatment.
The treatment was applied two or three times a
week, and the initial dose was determined as 30% of the
MED for patients with vitiligo and 50% of the MED for
patients with other conditions. The dose increments were
conducted at every session by evaluating the erythema
response, usually by 50 mJ/cm2 for patients with vitiligo
and 20% of the last dose for patients with other conditions.
The adverse effects associated with phototherapy, such as
erythema, pigmentation, itching, and bullae formation,
were evaluated before every session.
Clinical photographs of the patients were taken prior
to treatment and then every 4 weeks with the same camera,
in the same room, and with the same light conditions.
The treatment was continued until complete clearance or
maximum efficacy was achieved and discontinued when
patients had worsening lesions or side effects.
2.3. Subjective evaluation of severity of disease
Patients with lichen simplex chronicus (LSC),
palmoplantar psoriasis/eczema, and psoriasis vulgaris
were asked to subjectively evaluate the severity of pruritus
caused by their dermatological disorder every 4–8 weeks
using a visual analog scale (VAS) (0–10 cm).
2.4. Evaluation of response to treatment
The same dermatologist (KES) evaluated the response to
treatment by comparing the photographs and using the
physician’s global assessment.
In patients with alopecia areata (AA), the response to
treatment was assessed according to the rate of terminal
and vellus hair regrowth. In patients with vitiligo, the
response to treatment was evaluated according to the rate
of repigmentation; in patients with psoriasis, the presence
and improvement rate of erythema, desquamation,
and infiltration; in patients with LSC, the severity of
lichenification; and in patients with palmoplantar psoriasis/
eczema, the presence and improvement rate of infiltration,
erythema, desquamation, and fissures were compared
between pre- and posttreatment photos. In patients with
more than one lesion treated, final response to treatment
was determined through the global assessment of all
treated lesions. Accordingly, the treatment response was
defined as follows: no response (0%–25%), mild response
(25%–50%), moderate response (51%–75%), significant
response (76%–90%), and complete response (>90%).
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2.5. Statistical analysis
Statistical analysis was performed using SPSS 21.0 (IBM
Corp., Armonk, NY, USA). Descriptive statistical methods
were used in the analysis of the data. The mean, standard
deviation, and range were calculated in the analysis of
numerical variables. Categorical variables were assessed by
frequency analysis.
Although the occurrence of side effects and phototherapy
parameters were analyzed in all patients who had at least
one treatment session, the response to treatment was only
assessed in patients who had attended at least one followup visit during the treatment course. The last observation
carried forward was used for the analysis of treatment
outcomes in those patients who did not attend a follow-up.
The response rates were also evaluated separately in patients
whose treatment was finalized by a physician.
3. Results
A total of 173 patients were referred to our phototherapy
unit during the study period, whose demographic and
disease characteristics are summarized in Table 1. Sixteen
(9.2%) of the 173 patients were excluded from the study
as a result of nonattendance in the follow-up process. The
remaining 157 (91.8%) patients received more than one
session of therapy and attended at least one follow-up visit.
3.1. Vitiligo
From 50 patients with vitiligo, the targeted phototherapy
was used as a monotherapy in 25 patients, whereas the
remaining 25 patients received at least one concomitant
topical therapy (tacrolimus, corticosteroids, or
antioxidants).
3.2. Alopecia areata
Of the 34 patients with AA included in the study, the
targeted phototherapy was used as a monotherapy in all
patients, except for 1 patient who received concomitant
topical tacrolimus treatment.
3.3. Lichen simplex chronicus
Among the 26 patients with LSC, the targeted phototherapy
was used as a monotherapy in all patients, except for 8
patients who were also treated with topical tacrolimus,
corticosteroids, and antihistamines (Figure 1).
3.4. Palmoplantar psoriasis/eczema (PPP)
A total of 39 patients with palmoplantar psoriasis/eczema
were included in the analysis. The targeted phototherapy
was used as a monotherapy in 19 patients, whereas it was
combined with topical agents in 17 patients and acitretin
in 3 patients.
3.5. Psoriasis vulgaris
Of the 24 patients with plaque-type psoriasis vulgaris, the
targeted phototherapy was used as a monotherapy in 8
patients, whereas it was combined with topical agents in 15
patients and acitretin in 1 patient (Figure 2).
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Table 1. Demographic and disease characteristics of the patients.
Characteristics

Vitiligo

Alopecia
areata

Lichen simplex Palmoplantar
Psoriasis
chronicus
psoriasis/eczema vulgaris

Total

Number of patients

50

34

26

Age (years),
mean ± SD (range)

28.64 ± 12.86
(6–57)

Duration of disease (months),
mean ± SD (range)
Sex, n (%)

39

24

173

28.53 ± 8.06 47.46 ± 12.33
(10–48)
(28–80)

43.77 ± 15.12
(10–75)

39.42 ± 14.08
(14–72)

36.35 ± 14.85
(6–80)

57.75 ± 72.34
(2–276)

45 ± 60.39
(1–240)

54.92 ± 74.43
(1–360)

63.82 ± 79.70
(4–360)

115.92 ± 106.91
(3–360)

Female

27 (54)

13 (38.2)

17 (65.4)

29 (74.4)

16 (66.7)

102 (59)

Male

23 (46)

21 (61.8)

9 (34.6)

10 (25.6)

8 (33.3)

71 (41)

I

1 (2)

-

-

1 (2.6)

-

2 (1.2)

23 (46)

11 (32.4)

7 (26.9)

12 (30.8)

8 (33.3)

61 (35.3)

Skin phototype, II
n (%)
III

Previous
treatments,
n (%)

Treatment
frequency,
n (%)

18 (36)

15 (44.1)

14 (53.8)

25 (64.1)

15 (62.5)

87 (50.3)

IV

8 (16)

8 (23.5)

5 (19.2)

1 (2.6)

1 (4.2)

23 (13.3)

No treatment

6 (12)

4 (11.8)

3 (11.5)

3 (7.7)

2 (8.4)

18 (10.5)

Topical

39 (78)

30 (88.2)

23 (88.5)

27 (69.2)

18 (74.8)

137 (79.2)

Systemic

-

-

-

9 (23.1)

4 (16.8)

13 (7.5)

Phototherapy

5 (10)

-

-

-

-

5 (2.8)

1/week

-

-

-

3 (7.7)

-

3 (1.7)

2/week

30 (60)

10 (29.4)

9 (34.6)

22 (56.4)

10 (41.7)

81 (46.8)

3/week

20 (40)

24 (70.6)

17 (65.4)

13 (33.3)

14 (58.3)

88 (50.9)

4/week

-

-

-

1 (2.6)

-

1 (0.6)

For all patient groups, the demographic and treatment
characteristics are shown in Table 1. The phototherapy
parameters, treatment outcomes, and adverse effects are
summarized in Table 2.
4. Discussion
In this retrospective study, the safety and efficacy of
targeted NB-UVB therapy was evaluated in patients with
vitiligo, AA, LSC, palmoplantar psoriasis/eczema, or
psoriasis vulgaris who were treated at our phototherapy
unit between 2014 and 2016. Only a limited number of
previous studies have addressed the safety and efficacy
of targeted UVB treatment for the aforementioned
dermatological disorders.
Phototherapy is commonly used in the treatment of
vitiligo, particularly in head and neck lesions recalcitrant
to topical therapies. In the literature, the response rates
with conventional phototherapy modalities have been
reported to be 78%–100% with PUVA and 41%–100%
with NB-UVB. Monochromatic excimer laser (MEL),
a targeted phototherapy modality, has been reported to
induce ≥75% repigmentation in 16%–52% of patients (7).
Among the 46 patients with vitiligo, in whom the treatment
response was assessed, a moderate or better response

was observed in 11 (23.9%) of them. Of the patients in
whom the treatment course was finalized by a physician,
a moderate or better response was obtained in 7 (23.3%).
In a study that investigated the efficacy of NB-UVB in
vitiligo, Menchini et al. treated 734 patients with vitiligo
and reported >75% improvement in 70% of patients (8).
In a study by Majid and Imran, an excellent response
was obtained in approximately 63% of patients who were
treated once or twice weekly (9). Likewise, Lotti et al.
reported an improvement of ≥75% in 72% of 100 patients
(10). In another study, a repigmentation rate of 50%–100%
was observed in 31 of 40 patients (11). In contrast to the
high response rates reported in these studies, Klahan and
Asawanonda reported an improvement of ≥50% in only
15% of 15 patients, which was similar to the results of the
present study (12). Another study by Asawanonda et al.
reported 26%–50% pigmentation in 29 lesions of 6 patients
(13). The low response rates observed in our study can be
explained by the following: i) the response rates in different
areas of the body could not be evaluated separately due to
the retrospective nature of the study, and thus this approach
might have underestimated the treatment outcomes; ii)
a high number of patients were lost to follow-up; iii) a
high number of patients attended treatment irregularly;
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Figure 1. Patient with lichen simplex chronicus (a), showing an excellent response with residual hyperpigmentation (b) at the end of 32
sessions of treatment.

and iv) the mean number of 25 sessions might have been
inadequate to induce a moderate or better response, and
thus extension of the treatment period in future studies
might provide better results. Consistent with previous
studies, no adverse events occurred in 22 (44%) patients
with vitiligo, whereas the most common adverse event was
mild erythema, which was observed in 16 (32%) patients.
These findings demonstrate that targeted NB-UVB therapy
is a safe treatment in terms of acute adverse effects.
Although uncontrolled studies using conventional
phototherapy modalities have reported an improvement
rate of 15%–70%, high recurrence rates, lack of
randomized controlled trials, and an increased risk of
malignancy with the use of PUVA treatment limit the use
of conventional phototherapy for AA. Targeted excimer
laser therapy is an important treatment alternative with
response rates up to 41.5%, particularly in limited, patchy
AA (3,14,15). To the best of our knowledge, the present
study is the first to investigate the safety and efficacy of
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targeted NB-UVB therapy for AA. Bayramgürler et
al. used cabin-type phototherapy with NB-UVB for
AA, and an excellent response was obtained in 6 of 25
patients at the end of 46 treatment sessions. However,
because intramuscular corticosteroid therapy was used
concomitantly in 4 of 6 patients, the authors concluded
that NB-UVB was ineffective for use as a monotherapy for
AA (16). In our study, a moderate or better improvement
was obtained in 13 of 32 patients (40.6%) after a mean of
23.76 treatment sessions. The response rates were even
higher when the patients lost to follow-up were excluded
from the evaluation, with 9 of 17 (52.9%) patients showing
a complete response. The higher response rates observed
in the present study may be explained by the ability of the
targeted NB-UVB device to deliver higher doses of NBUVB. The response rates obtained in the present study are
comparable to those of studies using PUVA and targeted
MEL; this suggests that targeted NB-UVB monotherapy
is an effective treatment option for AA. The present study
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Figure 2. Patient with psoriasis displaying moderate improvement of hand and foot lesions, respectively (a–f), following 25 sessions of
treatment.

has two limitations: first, there was no control group due
the retrospective design of the study; second, spontaneous
remission may occur in AA. Despite these limitations,
it can be said that the response rates observed in the
present study can be attributed to NB-UVB therapy as a
majority of the patients had long-standing disease that was
recalcitrant to topical and/or intralesional treatments. In
agreement with previous studies, severe side effects and

discontinuation of treatment due to side effects occurred
in only one patient (2.9%), which supports the safety of
phototherapy modalities in patients with AA.
The efficacy of conventional phototherapy modalities
in the treatment of pruritic conditions such as prurigo
nodularis and uremic pruritus has been evidenced in many
studies (17,18). Regarding the efficacy of phototherapy in
the treatment of LSC, only a single study was found in
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Table 2. Phototherapy parameters, adverse effects, and treatment outcomes in treated patients.
Characteristics

Vitiligo

Alopecia areata

Lichen simplex Palmoplantar
Psoriasis
chronicus
psoriasis/eczema vulgaris

Number of patients

50

34

26

Minimal erythema dose (mJ/cm2),
mean ± SD (range)

372.36 ± 116.81 417.32 ± 161.26 387.5 ± 132.23 331.92 ± 119.41
(220–700)
(130–660)
(165–660)
(165–700)

403.96 ± 148.6
(145–700)

Initial dose (mJ/cm2),
mean ± SD (range)

138.38 ± 63.54
(68–350)

207.12 ± 80.38
(70–330)

170.69 ± 47.04 161.51 ± 62.13
(80–250)
(70–350)

194.42 ± 76.60
(72–350)

Cumulative dose (mJ/cm2),
mean ± SD (range)

17589 ± 21706
(90–93730)

18168 ± 16017
(710–71574)

23772 ± 28010 17070 ± 20202
(365–117644) (70–89870)

18328 ± 15998
(204–50391)

Maximum dose (mJ/cm2),
mean ± SD (range)

905 ± 609 (90–
2510)

1169 ± 574
(300–2665)

1028 ± 647
(144–2988)

1074 ± 706
(70–2748)

1201 ± 616
(120–2146)

Total number of sessions,
mean ± SD (range)

25.40 ± 19.03
(1–82)

23.76 ± 13.60
(2–54)

29.08 ± 24.24
(2–91)

19.54 ± 18.66
(1–104)

20.25 ± 11.75
(2–45)

None

22 (44)

9 (26.5)

18 (69.2)

32 (82.1)

12 (50)

Mild erythema

16 (32)

18 (52.9)

6 (23.1)

7 (17.9)

10 (41.6)

Moderate erythema

8 (16)

6 (17.6)

2 (7.7)

-

1 (4.2)

1 (2.9)

-

-

1 (4.2)

Adverse effects,
n (%)

Severe erythema/bullae 2 (4)
Hyperpigmentation

39

24

2 (4)

-

1 (3.8)

-

-

46

32

23

33

23

No response

28 (61)

9 (28.1)

4 (17.5)

7 (21.2)

2 (8.7)

Mild

7 (15.2)

10 (31.3)

2 (8.7)

7 (21.2)

8 (34.8)

Moderate

6 (13)

4 (12.5)

7 (30.4)

4 (12.1)

4 (17.4)

Significant

2 (4.3)

-

3 (13)

11 (33.4)

7 (30.4)

Complete

3 (6.5)

9 (28.1)

7 (30.4)

4 (12.1)

2 (8.7)

30

17

13

14

5

No response

17 (56.7)

4 (23.5)

1 (7.7)

2 (14.3)

-

Mild

6 (20)

3 (17.6)

1 (7.7)

1 (7.1)

-

Moderate

3 (10)

1 (5.9)

3 (23.1)

1 (7.1)

-

Significant

1 (3.3)

-

1 (7.7)

4 (42.9)

3 (60)

Complete

3 (10)

9 (52.9)

7 (53.8)

4 (28.6)

2 (40)

Number of patients

21

29

19

Visual analog scale Pretreatment
scores, mean ± SD Posttreatment

7.84 ± 2.26

4.55 ± 3.22

5.79 ± 3.66

1.96 ± 2.4

1.79 ± 2.96

2.79 ± 3.08

Number of patients
Treatment
outcome in all
patients assessed,
n (%)
Number of patients
Treatment
outcome in
patients whose
treatment was
stopped by
physician, n (%)

the literature. This study involved the use of targeted 308nm MEL therapy to treat 6 patients with LSC. The results
showed a complete response in one patient and a partial
response in the others (19). In another case, targeted NBUVB therapy was successfully used in a patient with vulvar
LSC (20). To the best of our knowledge, the present study
is not only the first to evaluate targeted NB-UVB therapy
for LSC, but it also has the highest number of patients
in comparison to other studies investigating the efficacy
of phototherapy for LSC. In the present study, a mean
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of 29 treatment sessions provided a moderate or better
response in 17 of 23 patients (73.8%) who were previously
unresponsive to topical treatments. After excluding 10
patients who were lost to follow-up from the analysis,
among the remaining 13 patients, 11 (84.6%) showed
a moderate or better response and 7 (53.8%) showed a
complete response. In addition to objective evidence of
efficacy, the posttreatment decrease in VAS scores confirms
the subjective efficacy of targeted NB-UVB therapy for
LSC resistant to topical measures. Among the responders,
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the mean number of sessions required to obtain the first
and excellent response were 10 and 19, respectively (data
not shown). These findings indicate that targeted NB-UVB
can provide a relatively rapid response that may improve
patients’ adherence to treatment. In addition, targeted NBUVB therapy has demonstrated a good safety profile in our
study, with no patients experiencing any severe side effects
or leaving treatment due to side effects.
The successful use of phototherapy modalities,
including PUVA, UVA1, and MEL, for the treatment
of palmoplantar psoriasis and pustulosis has been
demonstrated in numerous studies (21–24). The present
study is the third study in the literature to investigate the
use of targeted NB-UVB therapy for PPP. Previously, Sezer
et al. used a right-left comparative study to compare the
efficacy of PUVA and local NB-UVB in 25 patients; this
study reported an improvement rate of 85% and 61% with
PUVA and local NB-UVB, respectively, after 27 treatment
sessions (25). Kawada et al. reported an improvement
rate of 61.4% in 15 patients with palmoplantar psoriasis/
pustulosis after a mean of 13.7 treatment sessions (26).
In accordance with the literature, in the present study, a
moderate or better response was observed in 19 (57.5%)
of 33 patients after a mean of 19.54 treatment sessions.
When the patients lost to follow-up were excluded, a
complete and moderate or better response was observed in
4 (28.6%) and 9 (68.6%) patients, respectively. The higher
rates of response observed in the present study are most
likely due to a combination of targeted NB-UVB with
topical treatments and acitretin in 17 (43.7%) and 3 (7.7%)
patients, respectively. However, because a moderate or
better response was obtained in 10 (62.6%) of 16 patients
who received targeted NB-UVB as a monotherapy, it
is conceivable that targeted NB-UVB therapy could
be effectively used in patients with PPP as either a
monotherapy or in combination with topical treatments.
Considering the lower penetration of NB-UVB compared
to PUVA (1), future studies investigating the efficacy of
combined treatment with systemic/topical treatments
and NB-UVB are required, particularly in the treatment
of hyperkeratotic lesions. The decrease in the VAS scores
following treatment confirms that targeted NB-UVB
therapy is also effective subjectively. In agreement with
the literature, 32 (82.1%) of patients in the present study
did not experience any side effects, and the remaining 7
(17.9%) demonstrated only mild erythema, a result that
implies the safety of targeted NB-UVB therapy.
According to treatment guidelines, cabin-type
phototherapy with PUVA and NB-UVB phototherapy
are listed among the first-line therapies for moderate to
severe psoriasis (21,27). Regarding targeted phototherapy
modalities, numerous studies have demonstrated the
efficacy of 308-nm MEL therapy (4,6). However, there

have been limited studies on the efficacy of targeted UVB
therapy for plaque-type psoriasis, and, in most of these,
broad-band UVB (BB-UVB) has been administered. In a
study by Toll et al., 15 patients were treated with BB-UVB
and a complete response was observed in 3 patients and
an almost complete response in 5 patients (28). Lapidoth
et al. reported a 73% decrease in the psoriasis severity
index in 28 patients with psoriasis at the end of 18 sessions
of BB-UVB treatment (29). Kemeny et al. compared the
efficacy of high- and low-dose BB-UVB in 20 patients
and observed a 93% and 84% improvement, respectively
(30). In addition to studies involving BB-UVB, several
studies have investigated the efficacy of targeted NB-UVB
therapy for plaque-type psoriasis (31–33). For instance,
Amornpinyokeit and Asawanonda compared the efficacy
of targeted NB-UVB monotherapy and the combination of
targeted NB-UVB therapy and 8-methoxypsoralen cream
in 10 patients with psoriasis and found the combination to
be more effective (31). The present study had the highest
number of patients in the literature, with 24 patients
with psoriasis having been treated. After a mean of 20.25
treatment sessions, a moderate or better response was
observed in 13 patients (56.5%). When patients who
had any concomitant treatment were excluded from the
analysis, a moderate or better improvement was observed
in 4 (50%) out of 8 patients. Although the response rates
observed in our study are lower than those reported in
BB-UVB studies, they are higher than those with only DBUVB treatment. The VAS scores for pruritus decreased
from 5.79 to 2.79 following treatment. The results from
the present study suggest that targeted NB-UVB therapy
is an effective and safe alternative for treating localized,
recalcitrant psoriatic lesions, either as monotherapy or
combined with topical treatments.
The present study has some limitations, mostly arising
from its retrospective design. First, the absence of untreated
control lesions is a limiting factor in the evaluation of
treatment response, particularly in AA and vitiligo, which
are likely to resolve spontaneously. However, the fact that
the patients included in the study had a long duration
of disease and stable lesions reduces the likelihood of
spontaneous remission. Furthermore, although rare, the
occurrence of device breakdowns during the treatment
course might have negatively influenced the treatment
continuity, patients’ adherence to treatment, and thus
the treatment outcomes. An additional limitation of the
current study is the determination of MED on healthy
skin in all patients. Determination of MED in vitiligous
skin might have decreased the rate of adverse effects and
increased the patient adherence. Another limitation of
our study is that in patients who were treated for more
than one lesion, the treatment response of lesions located
in different anatomical regions was not compared. This
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might have resulted in lower than expected response to
treatment, particularly in patients with vitiligo. In future
studies, it would be of interest to compare the efficacy of
targeted NB-UVB therapy in various anatomical sites and
to evaluate the treatment response of individual lesions
rather than a global assessment. The lack of a follow-up
period for patients included in our study is another limiting
aspect of our research. Finally, the response rates between
the patients who received targeted NB-UVB therapy, as
either a monotherapy or concomitant with topical and/or
systemic agents, were not compared because of the small
sample size. A prospective study is planned to compare
the efficacy of various treatment combinations in different
conditions. The larger sample size of the present study in

comparison to previous studies and the use of standardized
treatment protocols are two main advantages. Another
strength is the fact that targeted NB-UVB therapy was
used for the first time for AA and LSC.
In conclusion, our findings demonstrate the safety
and efficacy of targeted NB-UVB therapy for vitiligo, AA,
LSC, palmoplantar psoriasis, and plaque-type psoriasis.
Results suggest that NB-UVB is a safe and highly
effective treatment option, particularly in AA, LSC, and
palmoplantar and plaque-type psoriasis recalcitrant to
topical treatments. In the future, prospective, randomized,
controlled studies investigating the efficacy of different
treatment combinations as well as the influence of patientand disease-related factors on response rates are warranted.
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